Effects of EPA on Cardiovascular Events Markers in Patients with Coronary Arery Disease

Conditions

Coronary Artery Disease

Tani S, Yagi T, Matsuo R, Kawauchi K, Atsumi W, Matsumoto N, Okumura Y.

2020-07-044 citations

10.1016/j.jjcc.2020.06.006

Administration of eicosapentaenoic acid may alter high-density lipoprotein heterogeneity in statin-treated patients with stable coronary artery disease: A 6-month randomized trial.

Tani S, Matsuo R, Yagi T, Matsumoto N.

2019-09-206 citations

10.1016/j.jjcc.2019.08.011

Does administration of eicosapentaenoic acid increase soluble thrombomodulin level in statin-treated patients with stable coronary artery disease?

Tani S, Matsuo R, Hirayama A.

2018-08-242 citations

10.1007/s00380-018-1240-3

The Ratio of Eicosapentaenoic Acid (EPA) to Arachidonic Acid may be a Residual Risk Marker in Stable Coronary Artery Disease Patients Receiving Treatment with Statin Following EPA Therapy.

Tani S, Nagao K, Kawauchi K, Yagi T, Atsumi W, Matsuo R, Hirayama A.

2017-10-019 citations

10.1007/s40256-017-0238-z

Impact of Adding Eicosapentaenoic Acid to Statin Therapy on Plasma Pentraxin 3 Level in Patients with Stable Coronary Artery Disease: A 6-Month, Randomized Controlled Study.

Tani S, Nagao K, Yagi T, Atsumi W, Hirayama A.

2017-02-0111 citations

10.1007/s40256-016-0195-y

Interventions

Administration of EPA Control

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with CAD.

Exclusion criteria

Exclusion criteria: The exclusion criteria included inability to obtain consent, current treatment with n-3PUFAs.

Design outcomes

Primary

Measure	Time frame
Changes in inflammatory biomarker	—

Countries

Japan

Contacts

Public ContactShigemasa Tani

Surugadai Nihon University Hospital Cardiology

tanishigem@yahoo.co.jp03-3293-1711

Outcome results

None listed